Abstracts tagged "B cells"

Abstract Number: 2197 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients
Divi Cornec¹, Alain Saraux², Jacques-Olivier Pers³, Sandrine Jousse-Joulin⁴, Yves Renaudineau³, Thierry Marhadour⁵ and Valerie Devauchelle-Pensec⁶, ¹Department of rheumatology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, ³Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁴Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ⁵Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁶Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France
Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative…
Abstract Number: 1746 • 2012 ACR/ARHP Annual Meeting
Semaphorin 3A Increases the Regulatory Characteristics of B-Regulatory Cells
Zahava Vadasz¹, Aharon Kessel² and Elias Toubi², ¹Clinical Immunology and Allergy, Bnai-Zion Medical Center, Haifa, Israel, ²Clinical Immunology and Allergy, Bnai-Zion Medical Center, Israel
Background/Purpose: Semaphorin3A (sem3A) and neuropilin-1 (NP-1), are important regulatory molecules, previously reported by us to play role in lupus glomerulonephritis. In a recent study we…
Abstract Number: 690 • 2012 ACR/ARHP Annual Meeting
Molecular Analysis of 9G4+ Antibodies in Systemic Lupus Erythematosus
Christopher Richardson¹, Asiya Seema Chida², Erin Fox¹, Lin Silver¹, Diana G. Adlowitz¹, Scott Jenks³, Elise Palmer¹, Christopher Tipton⁴ and Ignacio Sanz⁵, ¹University of Rochester, Rochester, NY, ²Medicine, Emory University Medical Center, Atlanta, GA, ³Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁴Medicine/Rheumatology, Emory University, Atlanta, GA, ⁵Rheumatology, Emory University, Atlanta, GA
Background/Purpose: Elevated titers of serum autoantibodies expressing the 9G4 idiotype are highly specific for SLE and correlate with disease activity and clinical manifestations. 9G4+ antibodies…
Abstract Number: 2071 • 2012 ACR/ARHP Annual Meeting
The Potent, Highly Selective and Orally Bioavailable Spleen Tyrosine Kinase Inhibitor GSK143 Demonstrates Efficacy in B Cell Receptor and Fc Receptor Signalling in Models of Inflammatory and Autoimmune Disease
Marion C. Dickson¹, Nicholas Smithers², Huw Lewis¹, Cesar Ramirez-Molina¹, Scott McCleary¹, Mike Barker¹ and John Liddle¹, ¹Immuno Inflammation, GSK, Stevenage, United Kingdom, ²Immuno Inflammation, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Spleen tyrosine kinase (Syk), a 72 KDa cytosolic non-receptor tyrosine kinase is a key mediator of B cell receptor (BCR) and Fc receptor (FcR)…
Abstract Number: 1749 • 2012 ACR/ARHP Annual Meeting
Targeting of CD22 by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation
N. Sieger¹, S.J. Fleischer¹, K. Reiter¹, H.E. Mei¹, A. Shock², G. Burmester¹, C. Daridon³ and Thomas Dorner¹, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²UCB Pharma, Slough, United Kingdom, ³Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine / German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany
Background/Purpose: CD22, a member of the sialic acid-binding immunoglobulin-like lectins (Siglec) family, is exclusively expressed on B cells at mature stage and is lost upon…
Abstract Number: 652 • 2012 ACR/ARHP Annual Meeting
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Venkat Reddy¹, Sara Croca², Delia Gerona³, Inmaculada De La Torre Ortega³, David A. Isenberg⁴, Maria Leandro² and Geraldine Cambridge⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ⁴Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁵Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in rituximab-induced B-cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in…
Abstract Number: 1783 • 2012 ACR/ARHP Annual Meeting
TNFα Influences RasGRP1 and RasGRP3 Expression Levels in PBMC, B and T Cells
Marie-Laure Potier¹, Martine Hiron¹, Clément Guillou¹, Céline Derambure², Olivier Boyer³, Xavier Le Loët⁴, Olivier Vittecoq⁵ and Thierry Lequerré⁶, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, Inserm 905, Institute for Biomedical research, University of Rouen, Rouen, France, ⁴Rheumatology Department, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁶Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T lymphocytes play a central role in the pathophysiology of RA. RasGRP is…
Abstract Number: 1751 • 2012 ACR/ARHP Annual Meeting
Effect of Repeated Infusions of Rituximab in Patients with Primary Sjögren’s Syndrome
Maria Perez-Ferro¹, Sheila Recuero², Fredeswinda I. Romero¹, Cristina Serrano³, Maria J. Rodriguez-Nieto⁴, Julio Gomez-Seco², Teresa Presa², Javier R. Godo², Gabriel Herrero-Beaumont⁵ and Olga Sanchez-Pernaute², ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Jimenez Díaz Foundation University Hospital, Madrid, Spain, ³Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Section for Autoimmune Diseases. Pneumology, Jimenez Díaz Foundation University Hospital, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: To assess the safety and efficacy of repeated infusions of rituximab (RTX) in patients with primary Sjögren syndrome (PSS). Methods: Patients with PSS were…
Abstract Number: 616 • 2012 ACR/ARHP Annual Meeting
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Wendy Cai¹, Cecil Chen¹, Z. John Zhong¹, William W. Freimuth¹, William Lewis² and David Subich³, ¹Human Genome Sciences, Inc., Rockville, MD, ²Covance Clinical Research Unit, Inc., Dallas, TX, ³Covance Clinical Research Unit, Inc., Daytona Beach, FL
Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the…
Abstract Number: 1758 • 2012 ACR/ARHP Annual Meeting
Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing After B Cell Depletion Therapy
Elena Becerra¹, Inmaculada de la Torre², Maria J. Leandro³ and Geraldine Cambridge³, ¹Rheumatology, University College London, London, United Kingdom, ²Rheumatology, Gregorio Marañón Hospital, Madrid, Spain, ³Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: B-cell-activating-factor (BAFF) coordinates differentiation of B cells into immunoglobulin secreting cells (ISC) by binding to 3 different receptors (BBRs), namely BAFF-R, transmembrane activator and…
Abstract Number: 1752 • 2012 ACR/ARHP Annual Meeting
Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing
Hamid Mattoo¹, Arezou Khosroshahi², Vinay Mahajan³, Mollie Carruthers², John Stone³ and Shiv Pillai⁴, ¹Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Massachusetts General Hospital, Boston, MA, ³Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Oncology, Massachusetts General Hospital, Boston, MA
Depletion of CD4-effector memory T cells and clonally expanded IgG4 memory B cells may explain the therapeutic efficacy of rituximab in IgG4-related disease: Studies using…
Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Thomas J. A. Lehman¹, Emily Baird², Anusha Ramanathan³, Risa Alperin³, Emma J. MacDermott³, Alexa B. Adams³, Laura V. Barinstein³ and Lakshmi N. Moorthy⁴, ¹Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, ²Hospital for Special Surgery, NY, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…
Abstract Number: 1759 • 2012 ACR/ARHP Annual Meeting
Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients
Abby Jones Weldon¹, Sheri Hsu², Seyed K. Nazeri³, Saru Sachdeva², Jennifer Gonzalez⁴, Andrea D. Parra⁵, Abigail Benitez¹, Keith K. Colburn⁶, Ioana Moldovan⁷ and Kimberly J. Payne⁸, ¹Microbiology and Molecular Genetics, Loma Linda University, Loma Linda, CA, ²Rheumatology, Loma Linda University Medical Center, Loma Linda, CA, ³Rheumatology, Loma Lida University Medical Center, Loma Lida, CA, ⁴Center of Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁵Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, ⁶Dept Med - Rheum Sect, Loma Linda Univ Medical Center, Loma Linda, CA, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA
Background/Purpose: Autoimmune disease affects more than 23 million Americans. Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) are chronic, systemic B-cell mediated autoimmune diseases. During…
Abstract Number: 1754 • 2012 ACR/ARHP Annual Meeting
Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response
Marieke E. Doorenspleet¹, Paul L. Klarenbeek¹, Maartje J. Boumans¹, Rogier M. Thurlings², Rebecca E. Esveldt¹, Barbera D. van Schaik³, Antoine H. van Kampen³, Danielle M. Gerlag⁴, Frank Baas⁵, Paul-Peter Tak¹, Robert M. Plenge⁶ and Niek de Vries¹, ¹Division of Clinical Immunology and Rheumatology, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Bioinformatics, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Genome Analysis, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, ⁶Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Autoreactive B lymphocytes are thought to play an important role in rheumatoid arthritis (RA). B-cell depletion therapy by rituximab (RTX) has shown that targeting…
Abstract Number: 610 • 2012 ACR/ARHP Annual Meeting
B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Eoghan M. McCarthy¹, Ruth Lee¹, Joan Ni Gabhann², Siobhan Smith², Michele Doran³, Gaye Cunnane³, Donough G. Howard¹, Paul G. O'Connell⁴, Grainne M. Kearns⁵ and Caroline Jefferies², ¹Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³Dept of Rheumatology, St. James Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ⁵Rheumatology Department, Beaumont Hospital, Dublin, Ireland
Background/Purpose: B Lymphocyte Stimulator(BLyS) plays an important role in the pathogenesis of Systemic Lupus Erythematosus(SLE). Whilst trials of anti BLyS-targeted therapy have shown promise, the optimal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].